- Home
- KNDI vs IMA Comparison
KNDI vs IMA Comparison
Compare KNDI & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNDI | IMA |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 66.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KNDI | IMA |
|---|---|---|
| Price | $0.63 | $4.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 70.6K | 9.7K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $3.94 |
| 52 Week High | $1.40 | $9.47 |
Technical Indicators
Market Signals| Indicator | KNDI | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 30.01 |
| Support Level | $0.61 | $3.94 |
| Resistance Level | $0.70 | $6.13 |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 46.97 | 4.30 |
Price Performance
Historical ComparisonAbout KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.